Calcitonin Salmon
Calcitonin Salmon is an FDA-approved calcitonin receptor agonist. Calcitonin binds the calcitonin receptor on osteoclasts, producing rapid loss of the ruffled border and reduced bone resorption, and acts at the renal tubule to increase calcium excretion. The salmon sequence binds the human receptor with higher affinity and is cleared more slowly than human calcitonin, which is why the salmon form is the one used clinically.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- 3431.9 g/mol
- Half-life
- —
- FDA status
- Approved
- Evidence level
- FDA Approved
- Human dose established
- Yes
- Administration Route
- Subcutaneous · Intramuscular · Intranasal
- Frequency
- Once daily (Paget's disease, osteoporosis); every 6–12 hours (hypercalcemia)
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Research summary
Synthetic 32-amino-acid polypeptide identical to salmon calcitonin, approved for Paget disease of bone, hypercalcaemia, and postmenopausal osteoporosis in women more than five years past menopause.
Research evidence
- Regulatory review (FDA label)4 reviewed sources
- Controlled human trialsNone in reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Calcitonin Salmon profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Calcitonin Salmon dosage evidence
Calcitonin salmon has FDA-approved human dosages. Miacalcin injection is 100 USP Units a day under the skin or into a muscle for Paget's disease of bone and for postmenopausal osteoporosis, and starts at 4 USP Units/kg every 12 hours for hypercalcemia (up to 8 USP Units/kg every 6 hours). The nasal spray for postmenopausal osteoporosis is one 200-unit spray a day, alternating nostrils.
| Human dosing established | Yes |
|---|---|
| Route | Subcutaneous · Intramuscular · Intranasal |
| Frequency | Once daily (Paget's disease, osteoporosis); every 6–12 hours (hypercalcemia) |
| Duration studied | Continuous for Paget's disease and osteoporosis, re-evaluated periodically |
| Titration | Hypercalcemia: 4 USP Units/kg every 12 hours; 8 USP Units/kg every 12 hours after 1–2 days if needed; then up to 8 USP Units/kg every 6 hours. |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Miacalcin injection, Paget's disease of boneFDA-approved label · FDA prescribing information | Adults with symptomatic Paget's disease of bone when alternative treatments are not suitable | 100 USP Units (0.5 mL) | Subcutaneous or intramuscular | Once daily | Continuous, re-evaluated periodically | Treatment of Paget's disease | MIACALCIN (calcitonin salmon) injection — FDA prescribing information, DailyMed |
| FDA label — Miacalcin injection, hypercalcemiaFDA-approved label · FDA prescribing information | Patients with hypercalcemia | Start 4 USP Units/kg; may increase to 8 USP Units/kg every 12 hours, then to a maximum of 8 USP Units/kg every 6 hours | Subcutaneous or intramuscular | Every 12 hours, up to every 6 hours | Early treatment of hypercalcemia | Lower serum calcium | MIACALCIN (calcitonin salmon) injection — FDA prescribing information, DailyMed |
| FDA label — Miacalcin injection, postmenopausal osteoporosisFDA-approved label · FDA prescribing information | Women more than 5 years past menopause with osteoporosis when alternative treatments are not suitable | 100 USP Units (0.5 mL) | Subcutaneous or intramuscular | Once daily | Continuous, with calcium and vitamin D | Treatment of postmenopausal osteoporosis; fracture reduction not demonstrated | MIACALCIN (calcitonin salmon) injection — FDA prescribing information, DailyMed |
| FDA label — calcitonin salmon nasal spray (generic, Apotex), postmenopausal osteoporosisFDA-approved label · FDA prescribing information, generic | Women more than 5 years past menopause with osteoporosis when alternative treatments are not suitable | 1 spray (200 USP Units) | Intranasal, alternating nostrils daily | Once daily | Continuous, with calcium and vitamin D | Treatment of postmenopausal osteoporosis; fracture reduction not demonstrated | Calcitonin salmon nasal spray (Apotex) — FDA prescribing information, DailyMed |
Where sources disagree
- Doses are in USP Units, not micrograms, and injected and nasal doses differ (100 units injected versus 200 units sprayed). DailyMed lists no current brand-name nasal spray; the nasal row uses a generic label.
- The labels report a higher rate of malignancy with calcitonin salmon than placebo in a meta-analysis of 21 trials (4.1% versus 2.9%), so they say to re-evaluate the need for continued therapy periodically.
Sequence & molecular data
| Molecular formula | C145H240N44O48S2 |
|---|---|
| Molecular weight | 3431.9 g/mol |
| PubChem CID | 16220016 |
| FDA UNII | 7SFC6U2VI5 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Calcitonin binds the calcitonin receptor on osteoclasts, producing rapid loss of the ruffled border and reduced bone resorption, and acts at the renal tubule to increase calcium excretion. The salmon sequence binds the human receptor with higher affinity and is cleared more slowly than human calcitonin, which is why the salmon form is the one used clinically.
Studies
- Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes
- [The preliminary results of research on salcatonin treatment in the surgical therapy of jaw cysts]
- Effect of salcatonin given intranasally on early postmenopausal bone loss
- Calcitonin intranasal--unigene: Salcatonin intranasal--unigene
- Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures
Research statistics
1,766 PubMed publications · 31.3% human clinical research · 19 registered trials
Counts of published research through 2026-11-08, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Calcitonin Salmon is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
How FDA approval, compounding and research-only status differ
Benefits
—
Calcitonin Salmon side effects
No side effects listed yet for this entry.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Calcitonin Salmon: frequently asked questions
What is Calcitonin Salmon?
Synthetic 32-amino-acid polypeptide identical to salmon calcitonin, approved for Paget disease of bone, hypercalcaemia, and postmenopausal osteoporosis in women more than five years past menopause.
How does Calcitonin Salmon work?
Calcitonin binds the calcitonin receptor on osteoclasts, producing rapid loss of the ruffled border and reduced bone resorption, and acts at the renal tubule to increase calcium excretion. The salmon sequence binds the human receptor with higher affinity and is cleared more slowly than human calcitonin, which is why the salmon form is the one used clinically.
Is Calcitonin Salmon FDA approved?
Yes. Calcitonin Salmon is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Calcitonin Salmon?
Compounds most often compared with Calcitonin Salmon include Elamipretide (SS-31) and Methylene Blue. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes — Drugs, 2015External reference
- [The preliminary results of research on salcatonin treatment in the surgical therapy of jaw cysts] — Minerva Stomatol, 1991External reference
- Effect of salcatonin given intranasally on early postmenopausal bone loss — BMJ, 1989External reference
- Calcitonin intranasal--unigene: Salcatonin intranasal--unigene — Drugs R D, 2004External reference
- Calcitonin (FORTICAL, MIACALCIN) for the treatment of vertebral compression fractures — Orthop Rev (Pavia), 2021External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Calcitonin Salmon profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Calcitonin Salmon research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →